Click here to load reader

  · Web view# Searches. Results. 1. exp Kidney Failure, Chronic/ 122462. 2. exp end stage renal disease/ 87207. 3 ("chronic kidney failure" or "chronic renal failure" or "end

  • View
    212

  • Download
    0

Embed Size (px)

Text of   · Web view# Searches. Results. 1. exp Kidney Failure, Chronic/ 122462. 2. exp end stage renal...

Table of ContentsSEARCH STRATEGY3Table I: Characteristics of the included studies:8Table II: Outcomes (rate, 95% confidence interval) per vascular access type:27Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:28III.1: Arteriovenous fistula (AVF), unspecified location:28III.2: Upper arm AVF:30III.3: Brachial- Basilic fistula:30III.4: Brachial-brachial fistula:31III.5: Brachial-Cephalic fistula:32III.6: Forearm AVF:33III.7: Radiocephalic fistula:34III.8: Forearm basilic fistula:37III.9: Lower extremity fistula:37III.10: Arteriovenous graft (AVG), unspecified location:38III.11: Upper arm graft:39III.12: Forearm graft:40III.13: Axillary-Axillary graft:40III.14: Lower extremity graft:41III.15: Tunneled cuffed catheter, unspecified location:41III.16: Tunneled cuffed IJ/subclavian PermCath:42III.17: Hybrid graft and catheter (HeRO):42Table IV: Average days to maturation:44Table V: Summary results of meta-analysis of included comparative studies per access types:45V.1: AVF, unspecified location:45V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:47V.3: Forearm AVF VS. Upper-arm AVF:49V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:49V.5: AVG, unspecified location VS. AVF, unspecified location:50V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:51References:54

SEARCH STRATEGY

Ovid

Database(s): Embase 1988 to 2014 Week 45, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials October 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2014 Search Strategy:

#

Searches

Results

1

exp Kidney Failure, Chronic/

122462

2

exp end stage renal disease/

87207

3

("chronic kidney failure" or "chronic renal failure" or "end stage kidney disease" or "end stage kidney failure" or "end stage renal disease" or "end stage renal dysfunction" or "end stage renal failure" or "end stage renal impairment" or "end stage renal insufficiency" or "end-stage kidney disease" or "end-stage renal disease" or "end-stage renal failure" or ESRD or "stage 5 kidney disease" or "stage 5 renal disease").mp.

132847

4

or/1-3

182614

5

exp hemodialysis/

161300

6

exp Renal Dialysis/

208945

7

((dialys* adj (center* or centre*)) or "acetate free biofiltration*" or "blood dialys*" or "extracorporeal blood cleansing" or "extracorporeal dialys*" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or "kidney dialys*" or "peritoneal dialys*" or "renal dialys*").mp.

226829

8

or/5-7

245229

9

(longterm or "long-term" or chronic*).mp.

3295608

10

8 and 9

111324

11

(((dialys* or "acetate free biofiltration*" or "extracorporeal blood cleansing" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or site or route or fistula* or catheter*) adj3 access*) or "Atrial graft*" or "Axillary axillary graft*" or "Brachial-basilic*" or "Brachial-brachial" or "Brachial-cephalic*" or "Cimino-radialcephalic*" or "Forearm basilic*" or "Forearm loop graft*" or HeRO or "Lower extremity fistula*" or "Lower extremity graft*" or permacath* or "perma-cath*" or "Upper arm graft*").mp.

24338

12

4 and 10 and 11

2369

13

exp evidence based medicine/

733513

14

exp meta analysis/

138861

15

exp Meta-Analysis as Topic/

30717

16

exp "systematic review"/

81374

17

exp Guideline/ or exp Practice Guideline/

347880

18

exp controlled study/

4554829

19

exp Randomized Controlled Trial/

738405

20

exp triple blind procedure/

75

21

exp Double-Blind Method/

346819

22

exp Single-Blind Method/

52137

23

exp latin square design/

277

24

exp Placebos/

271059

25

exp Placebo Effect/

7405

26

exp comparative study/

2493767

27

exp Cross-Sectional Studies/

319507

28

exp Cross-Over Studies/

102747

29

exp Cohort Studies/

1725548

30

exp longitudinal study/

1091483

31

exp retrospective study/

885368

32

exp prospective study/

717147

33

exp population research/

68686

34

exp observational study/

68797

35

exp clinical trial/

1757706

36

clinical study/

55043

37

exp Evaluation Studies/

215521

38

exp Evaluation Studies as Topic/

1159447

39

exp quantitative study/

6007

40

exp validation studies/

116990

41

exp experimental study/

15098

42

exp quasi experimental study/

2125

43

in vivo study/

192702

44

exp panel study/

382

45

exp Pilot Projects/

175019

46

exp pilot study/

175019

47

exp prevention study/

2192

48

exp replication study/

985

49

exp theoretical study/

1426309

50

exp Feasibility Studies/

102071

51

exp trend study/

11615

52

exp correlational study/

11871

53

exp case-control studies/

808393

54

exp confidence interval/

124913

55

exp regression analysis/

589967

56

exp proportional hazards model/

99355

57

exp multivariate analysis/

352620

58

((evidence adj based) or (outcome* adj (research or assessment*)) or (meta adj analys*) or (systematic* adj3 review*) or guideline* or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo* or nocebo* or random* or control* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or compar* or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") adj3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "population study" or "population survey" or "population analysis" or "population research" or "concurrent study" or "concurrent survey" or "concurrent analysis" or "incidence study" or "incidence survey" or "incidence analysis" or (("follow-up" or followup) adj (stud* or survey or analysis)) or ((observation or observational) adj (study or survey or analysis)) or "case study" or "case series" or "clinical series" or "case studies" or "clinical study" or "clinical trial" or "evaluation study" or "evaluation survey" or "evaluation analysis" or "quantitative study" or "quantitative analys*" or "numerical study" or "validation study" or "validation survey" or "validation analysis" or "experimental study" or "experimental analysis" or "quasi experimental study" or "quasi experimental analysis" or "quasiexperimental study" or "quasiexperimental analysis" or "field study" or "field survey" or "field analysis" or "in vivo study" or "in vivo analysis" or "panel study" or "panel survey" or "panel analysis" or "pilot study" or "pilot survey" or "pilot analysis" or "pilot project" or ((prevention or preventive) adj3 (trial or study or analysis or survey)) or "replication study" or "replication analysis " or "replication trial" or "theoretical study" or "theoretical analysis " or "feasibility study" or "feasibility analysis" or "trend study" or "trend survey" or "trend analysis" or ((correlation* adj2 study) or (correlation* adj2 analys*)) or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multi-center study" or study or trial or pilot or "odds ratio" or "confidence interval" or "regression analysis" or "least square" or "least squares" or (hazard* adj (model or analys* or regression)) or "Cox model" or "Cox multivariate analyses" or "Cox multivariate analysis" or "Cox regression" or "Cox survival analyses" or "Cox survival analysis" or "Cox survival model" or "change analysis" or ((study or trial or random* or control*) and compar*)).mp,pt.

22826290

59

or/13-58

23725706

60

12 and 59

1697

61

from 12 keep 902-2274

1373

62

limit 61 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or controlled clinical trial or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or comparative study or controlled clinical trial or evaluation studies or guideline or practice guideline or meta analysis or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or systematic reviews or validation studies) [Limit not valid in Embase,CCTR,CDSR; records were retained]

365

63

60 or 62

1697

64

limit 63 to (book or book series or editorial or erratum or letter or note or addresses or autobiography or bibliography or biography or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were retained]

50

65

63 not 64

1647

66

from 12 keep 2275-2369

95

67

65 or 66

1664

68

limit 67 to ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)") [Limit not valid in Embase,CCTR,CDSR; records were retained]

1418

69

limit 68 to (adult or aged ) [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were retained]

1167

70

67 and (adult or adults or "middle age" or "middle aged").mp.

1101

71

69 or 70

1209

72

limit 71 to yr="1970 -Current"

1209

73

remove duplicates from 72

837

Table I: Characteristics of the included studies:

Study ID

Patients characteristic

Co Intervention

Cohort selection

Lost to follow up

Cante, 19981

End stage renal disease (ESRD)

NA

None reported or unclear sampling

Not reported

Dhingra, 20012

ESRD

NA

Our experience (All patients)

Not reported

Keuter, 20083

Patients with radiocephalic or brachiocephalic arteriovenous fistulas failure, on aspirin unless already on anticoagulation

NA

Our experience (All patients)

Not reported

DAyala, 20084

ESRD

Systemic heparin 57 patients

a consecutive sample

2.609

Fassiadis, 20075

ESRD

NA

a consecutive sample

Not reported

Elwakeel, 20076

ESRD with no suitable superficial vein

NA

Our experience (All patients)

Not reported

Keeling, 2007 7

ESRD

NA

a consecutive sample

7.965

Nikeghbalian, 20068

ESRD

NA

Our experience (All patients)

Not reported

MAYA, 20059

ESRD

NA

Our experience (All patients)

Not reported

Rooijens, 2005 10

ESRD

NA

a consecutive sample

3.846

Madden, 2005 11

ESRD

NA

Our experience (All patients)

Not reported

Chen, 200512

ESRD

Outflow Venovenostomy

Our experience (All patients)

0

Akoh, 200513

ESRD

NA

Our experience (All patients)

0.45

Brueck, 2004 14

ESRD

NA

a consecutive sample

Not reported

Di Iorio, 200415

ESRD

NA

Our experience (All patients)

Not reported

Rao, 2004 16

ESRD

NA

Our experience (All patients)

27

KAO, 200417

ESRD

NA

Our experience (All patients)

Not reported

Flarup, 200318

ESRD

NA

Our experience (All patients)

Not reported

Segal, 200319

ESRD

NA

Our experience (All patients)

Not reported

Gallieni, 2002 20

ESRD

NA

Our experience (All patients)

Not reported

Hingorani, 2001 21

ESRD

NA

Our experience (All patients)

Not reported

Berman, 200122

ESRD

NA

Our experience (All patients)

Not reported

vogel, 200023

ESRD

NA

a consecutive sample

0

Miller, 1999 24

ESRD

NA

Our experience (All patients)

2.58621

khadra, 1997 25

ESRD

NA

Our experience (All patients)

Not reported

PALDER, 1985 26

ESRD

NA

Our experience (All patients)

Not reported

Rabbani, 2006 27

ESRD

NA

Our experience (All patients)

Not reported

SENKAYA, 200628

ESRD

NA

Our experience (All patients)

Not reported

Hood, 199429

ESRD

Percutaneous balloon angioplasty

Our experience (All patients)

Not reported

BRUNORI, 200030

ESRD

NA

Our experience (All patients)

Not reported

Choi, 200331

ESRD

NA

a consecutive sample

0

Dixon, 200232

ESRD

NA

Our experience (All patients)

Not reported

Matsuura, 199833

ESRD

NA

a consecutive sample

Not reported

Silva, 199834

ESRD

Doppler pressures and duplex ultrasound with mapping

Our experience (All patients)

Not reported

Staramos, 200035

ESRD

NA

a consecutive sample

1.75

Kokkosis, 2013 36

Cardiovascular comorbidity

NA

Our experience (All patients)

0

Goldfarb-Rumyantze, 201337

Renal transplantation

NA

None reported or unclear sampling

Not reported

Al-Benna, 201338

ESRD

NA

Our experience (All patients)

Not reported

Sahin, 2011 39

ESRD

Duplex Doppler

Our experience (All patients)

0

Chiulli, 201140

ESRD

NA

Our experience (All patients)

Not reported

Bonforte, 2010 41

ESRD

NA

Our experience (All patients)

Not reported

Ferring, 201042

ESRD

NA

Our experience (All patients)

0

Kybartiene, 201043

ESRD

Antibiotics

Our experience (All patients)

2

Stuard, 201044

ESRD

Clopidogrel or aspirin with or without heparin

Our experience (All patients)

Not reported

Garcia Cortes, 200545

ESRD

NA

None reported or unclear sampling

Not reported

Jimenez-Almonacid, 2004 46

ESRD

NA

a consecutive sample

Not reported

Hernandez-Jaras, 200447

ESRD

NA

Our experience (All patients)

Not reported

Rodriguez, 200148

ESRD

NA

Our experience (All patients)

Not reported

Branger, 201149

ESRD

NA

Our experience (All patients)

Not reported

Kennealey, 201150

ESRD

NA

Our experience (All patients)

Not reported

Diehm, 201051

ESRD

NA

Our experience (All patients)

Not reported

Wasse, 200852

ESRD

NA

Our experience (All patients)

Not reported

Ko, 200953

Patients without suitable superficial veins

NA

Our experience (All patients)

Not reported

Slayden, 200854

ESRD

converting arteriovenous grafts to Secondary arteriovenous fistulas

a consecutive sample

Not reported

EKBAL, 200855

ESRD

NA

Our experience (All patients)

Not reported

Tsoulfas, 200856

ESRD

NA

Our experience (All patients)

Not reported

Long, 200857

ESRD with peri anastomotic stenosis

Surgery or angioplasty

Our experience (All patients)

0

Qasaimeh, 200858

ESRD

NA

Our experience (All patients)

0

Bronder, 200859

ESRD

Fistula Elevation Procedure

Consecutive

Not reported

Torina, 200860

ESRD

NA

Our experience (All patients)

Not reported

Shahnawaz, 201361

ESRD

NA

Our experience (All patients)

Not reported

Morale, 201162

ESRD

NA

Our experience (All patients)

10

Lee, 201163

ESRD

Preoperative ultra sound

None reported or unclear sampling

Not reported

Moussavi, 200764

ESRD

NA

a consecutive sample

Not reported

Savader, 200065

ESRD

NA

Our experience (All patients)

Not reported

Hurlbert, 199866

ESRD

NA

a consecutive sample

0

McLaughlin, 199767

ESRD

Antibiotics 1 g IV vancomycin

Our experience (All patients)

Not reported

Ozlem, 199668

ESRD

NA

Our experience (All patients)

Not reported

Tedoriya, 199569

ESRD

NA

Our experience (All patients)

Not reported

Beigi, 200970

ESRD

NA

a consecutive sample

Not reported

Gormus, 200371

ESRD

NA

None reported or unclear sampling

Not reported

Polo, 200472

ESRD

NA

a consecutive sample

0

Ascher, 200173

ESRD

Preoperative ultra sound

Our experience (All patients)

Not reported

Astor, 200574

ESRD

NA

Our experience (All patients)

Not reported

Coburn, 199475

ESRD

NA

Our experience (All patients)

1.235

Haimov, 198076

ESRD

NA

Our experience (All patients)

Not reported

Hazinedaroglu, 200477

ESRD

Preoperative venography, prophylactic dose of 1.5 g ampicillin + sulbactam IV

Our experience (All patients)

Not reported

Kherlakian, 198678

ESRD

NA

Our experience (All patients)

Not reported

Kim, 199579

ESRD

NA

Our experience (All patients)

Not reported

Oliver, 200180

ESRD

NA

None reported or unclear sampling

3.77

Perera, 200481

ESRD

NA

a consecutive sample

13.39713

Polkinghorne, 200482

ESRD in Australia and New Zealand

NA

Our experience (All patients)

0

Ridao-Cano, 200283

ESRD

Preoperative venography

Our experience (All patients)

4.931

Sparks, 199784

ESRD

NA

Our experience (All patients)

Not reported

Tordoir, 198385

ESRD

NA

Our experience (All patients)

Not reported

Shemesh, 200886

Recurrent cephalic arch stenosis >50% within 3 months of successful balloon angioplasty

Endovascular intervention + preoperative ultra sound

a consecutive sample

0

Flu, 200887

ESRD

NA

a consecutive sample

0

Kakkos, 200888

ESRD

NA

a consecutive sample

0.5

Wu, 200889

ESRD with access dysfunction

Balloon angioplasty for dialysis access dysfunction or thrombosis

Our experience (All patients)

Not reported

Kakkos, 200890

ESRD

NA

a consecutive sample

Not reported

Jean -Baptiste, 200891

ESRD

Preoperative ultra sound

Our experience (All patients)

0

Schild, 200792

ESRD HIV without sufficient veins for an autologous fistula

NA

a consecutive sample

Not reported

Moossavi, 200793

ESRD

Surgeon experience, interventional radiologists, intervention within 48 hours of thrombosis

a consecutive sample

Not reported

Woo, 200794

ESRD

Preoperative ultra sound

Our experience (All patients)

Not reported

Kayacioglu, 200795

ESRD, with diabetes

NA

None reported or unclear sampling

Not reported

Lee, 200796

ESRD

Preoperative mapping, Surgeon experience

Our experience (All patients)

Not reported

Shemesh, 200797

ESRD

Single dose of Cefamezine

a consecutive sample

1.515

Basaran, 200798

ESRD

Anti-platelets aspirin 300 mg/day

None reported or unclear sampling

Not reported

Korten, 200799

ESRD

Preoperative ultra sound

a consecutive sample

Not reported

Yilmaz, 2007100

ESRD, 1-4 previous access attempts

NA

a consecutive sample

7.1

Mitchell, 2007101

ERSD HIV (+) vs. (-)

NA

Our experience (All patients)

Not reported

Inrig, 2006102

ESRD, Patients with Staphylococcus aureus Bacteremia

Surgical and percutaneous treatment of thrombosis, preoperative ultra sound

Our experience (All patients)

0

Karakayali, 2006103

ESRD

NA

Our experience (All patients)

Not reported

El Sayed, 2005104

ESRD

Preoperative ultra sound

Our experience (All patients)

14.1

Fitzgerald, 2005105

ESRD

Preoperative ultra sound, preoperative venography

Our experience (All patients)

Not reported

Modarai, 2005106

ESRD, Radiocephalic, brachiocephalic and brachiobasilic fistulas not possible

NA

Our experience (All patients)

Not reported

Kizilisik, 2004107

ESRD

NA

Our experience (All patients)

Not reported

Ko, 2004108

ESRD

NA

a consecutive sample

Not reported

Fitzgerald, 2004109

ESRD

NA

Our experience (All patients)

Not reported

Mazzoni, 2003110

ESRD

Preoperative ultra sound

Our experience (All patients)

0

Senkaya, 2003111

ESRD

300mg aspirin

None reported or unclear sampling

0

Xue, 2003112

ESRD

NA

a consecutive sample

Not reported

Shenoy, 2003113

ESRD

NA

Our experience (All patients)

Not reported

Bruns, 2003114

ESRD

NA

Our experience (All patients)

8.2

Wiese, 2003115

ESRD, absence of sufficient native vessels to create an AV fistula

Color Doppler ultrasound

Our experience (All patients)

6.7

Baldrati, 2003116

ESRD

NA

a consecutive sample

Not reported

Hossny, 2003117

ESRD

NA

Our experience (All patients)

2.857

Dalman, 2002118

ESRD

NA

a consecutive sample

Not reported

Sorom, 2002119

ESRD

Preoperative ultra sound, 1 aspirin daily

a consecutive sample

Not reported

Ascher, 2001120

ESRD

NA

Our experience (All patients)

Not reported

Wolowczyk, 2000121

ESRD

NA

Our experience (All patients)

35

Taylor, 1996122

ESRD

First generation cephalosporin or vancomycin given at dialysis

a consecutive sample

Not reported

Helling, 1992123

ESRD

NA

a consecutive sample

Not reported

Nannery, 1991124

ESRD, HIV, IV drug abusers

NA

Our experience (All patients)

0

Donnelly, 1988125

ESRD

Heparin

Our experience (All patients)

Not reported

Rizzuti, 1988126

ESRD

Antibiotics

Our experience (All patients)

Not reported

Elwakeel, 2013127

ESRD patients with no suitable vein to perform autogenous arteriovenous fistulas

Preoperative ultra sound

Our experience (All patients)

Not reported

Fredette, 2013128

ESRD in Octogenarian (>80 years old)

Vascular mapping

Our experience (All patients)

Not reported

Scarritt, 2014129

ESRD not appropriate candidates for a primary fistula

NA

a consecutive sample

Not reported

Hruby, 2013130

ESRD

Duplex Doppler Ultrasound

Our experience (All patients)

Not reported

Kanko, 2012131

ESRD

NA

a consecutive sample

Not reported

Gage, 2012132

ESRD

NA

Our experience (All patients)

Not reported

Basel, 2011133

ESRD

Duplex scanning

a consecutive sample

Not reported

Walker, 2012134

ESRD

Duplex scanning

Our experience (All patients)

Not reported

Huddam, 2012135

ESRD

NA

None reported or unclear sampling

Not reported

Woo, 2012136

ESRD

NA

Our experience (All patients)

Not reported

Lukowsky, 2012137

ESRD

NA

Our experience (All patients)

Not reported

Solid, 2012138

ESRD

NA

Our experience (All patients)

Not reported

Matsumoto, 2012139

ESRD

Preoperative ultra sound

Our experience (All patients)

Not reported

Desilva, 2012140

ESRD

NA

Our experience (All patients)

Not reported

Vahedian, 2012141

ESRD

Preoperative ultra sound

Our experience (All patients)

0

Jackson, 2011142

ESRD with Angiotensin receptor blocker VS. No Angiotensin receptor blocker

NA

None reported or unclear sampling

Not reported

Chan, 2011143

ESRD

NA

Our experience (All patients)

Not reported

Conte, 2011144

ESRD, Cardiovascular comorbidity

Vascugel or placebo prior to surgery

None reported or unclear sampling

6.45

Powell, 2010145

ESRD

Preoperative ultra sound, preoperative venography

None reported or unclear sampling

Not reported

Karakayali, 2007146

ESRD

Preoperative ultra sound, preoperative venography

a consecutive sample

Not reported

Hamida, 2005147

ESRD

NA

None reported or unclear sampling

Not reported

Cetinkaya, 2003148

ESRD

NA

None reported or unclear sampling

Not reported

Gorski, 2002149

HIV

NA

a consecutive sample

Not reported

Ravani, 2002150

ESRD

Preoperative ultra sound

a consecutive sample

Not reported

BACCHINI, 2001151

ESRD, impairment of native AVF

NA

None reported or unclear sampling

Not reported

Friedman, 2000152

ESRD

NA

None reported or unclear sampling

5.83

Leapman, 1995153

ESRD

NA

None reported or unclear sampling

0

Cohen, 1994154

ESRD who underwent thrombolysis for thrombosed hemodialysis

Percutaneous transluminal balloon angioplasty

Our experience (All patients)

13

Viron, 1987155

ESRD

NA

None reported or unclear sampling

Not reported

Weale, 2008156

ESRD

Preoperative ultra sound

Our experience (All patients)

14.29

Gargiulo, 1999157

ESRD

Antibiotics, preoperative ultra sound

Our experience (All patients)

17.65

Mortazavi, 2011158

ESRD

NA

Our experience (All patients)

0

Gibson, 2001159

ESRD

NA

a consecutive sample

Not reported

Taylor, 1993160

ESRD

NA

None reported or unclear sampling

Not reported

Morosetti, 2011161

ESRD

Ceftazidime (1 g) was administered as a single-dose therapy

a consecutive sample

Not reported

Chen, 2010162

ESRD

NA

None reported or unclear sampling

Not reported

Gonzalez, 2010163

ESRD

NA

a consecutive sample

Not reported

Dember, 2008164

ESRD

Preoperative ultra sound

a consecutive sample

3.763

Louridas 165, 1984

ESRD

NA

Our experience (All patients)

Not reported

Foley, 2009166

ESRD

NA

a consecutive sample

Not reported

Salman, 2009167

ESRD

Preoperative venography

Our experience (All patients)

Not reported

Bradbury, 2009168

ESRD

NA

a consecutive sample

Not reported

Pisoni, 2009169

ESRD

NA

a consecutive sample

Not reported

Bhomi, 2008170

ESRD

5000 IU of intravenous heparin during surgery vs no heparin

a consecutive sample

Not reported

Grubbs, 2013171

ESRD

NA

Our experience (All patients)

Not reported

Jemcov, 2013172

ESRD

Preoperative ultra sound

a consecutive sample

Not reported

Alhassan, 2013173

ESRD in Nigerians

NA

a consecutive sample

2.87

Ilhan, 2013174

ESRD

Preoperative ultra sound

Our experience (All patients)

Not reported

Manson, 2012175

ESRD

Opti-Flow Vascular Anastomosis Device

None reported or unclear sampling

Not reported

Wongkonkitsin, 2014176

ESRD in Thai

Preoperative ultra sound

Our experience (All patients)

Not reported

Watorek, 2014177

ESRD in Octogenarian (>80 years old)

NA

Our experience (All patients)

Not reported

Wetzig, 1985178

ESRD

Preoperative venography, bilateral upper extremity central venograms

a consecutive sample

0

Hart, 2014179

ESRD

NA

Our experience (All patients)

0

Persic, 2013180

ESRD

Preoperative ultra sound

Our experience (All patients)

2.5

Prischl, 1995181

ESRD

Preoperative ultra sound

a consecutive sample

Not reported

Kaufman, 1997182

ESRD

Preoperative ultra sound

a consecutive sample

1.7

Lok, 2005183

ESRD

NA

a consecutive sample

Not reported

Vaux, 2013184

ESRD

NA

Our experience (All patients)

0

Bender, 1995185

ESRD

NA

Our experience (All patients)

Not reported

Yasuhara, 1997186

ESRD

NA

Our experience (All patients)

Not reported

Wang, 1996187

ESRD

Antibiotics

Our experience (All patients)

Not reported

kalman, 1999188

ESRD

NA

a consecutive sample

Not reported

ELCHEROTH, 1994189

ESRD

NA

Our experience (All patients)

Not reported

Simoni, 1994190

ESRD

NA

Our experience (All patients)

Not reported

Rubens, 1993191

ESRD

NA

Our experience (All patients)

Not reported

BURT, 2001192

ESRD

NA

a consecutive sample

Not reported

Golledge, 1999193

ESRD

NA

our experience (All patients)

not reported

Lemson, 2000194

ESRD

Antibiotics

a consecutive sample

not reported

Curi, 1999195

ESRD HIV (+) vs. (-)

NA

our experience

1.92%

Munda, 1983196

ESRD

NA

our experience (all patients)

not reported

Silva, 1997197

ESRD

Preoperative ultra sound

our experience (all patients)

0

Hakaim, 1997198

ESRD

NA

our experience (all patients)

not reported

Bone, 1980199

ESRD

1 g of cephalothin

a consecutive sample

not reported

Hibberd, 1991200

ESRD primary vascular access was not possible

All had pre-operative upper limb venography

a consecutive sample

not reported

Table II: Outcomes (rate, 95% confidence interval) per vascular access type:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Arteriovenous fistula

0.548 (0.522- 0.576) at 104 weeks*

0.627 (0.586- 0.670) at 104 weeks

0.787 (0.743- 0.834) at 65 weeks

0.153 (0.125- 0.187) at 104 weeks

0.827 (0.773- 0.885) at 26 weeks

0.021 (0.010 - 0.043) at 104 weeks

Arteriovenous graft

0.395 (0.353- 0.442) at 104 weeks

0.599 (0.548- 0.653) at 104 weeks

0.527 (0.422- 0.658) at 52 weeks

0.170 (0.135- 0.215) at 71.5 weeks

0.960 (0.858- 1.074) at 39 weeks

0.127 (0.097- 0.166) at 104 weeks

Catheter

0.499 (0.408-0.609) at 86 weeks

0.429 (0.267-0.687) at 39 weeks

0.763 (0.499-1.165) at 26 weeks

0.256 (0.203- 0.323) at 112 weeks

0.164 (0.078-0.344) at 59 weeks

HeRO

0.429 (0.361-0.510) at 104 weeks

0.704 (0.391-1.270) at 78 weeks

0.178 (0.128-0.248) at 122.8 weeks

0.038 (0.016-0.086) at 122.8 weeks

*The follow up is reported as median for all outcomes.

Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:III.1: Arteriovenous fistula (AVF), unspecified location:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.556 (0.512-0.605) at 91 weeks

0.652 (0.590-0.720) at 104 weeks

0.687 (0.580-0.812) at 52 weeks

0.152 (0.117-0.196) at 69 weeks

0.813 (0.676-0.978) at 19.5 weeks

0.023 (0.007-0.074) at 93 weeks

Age 65.

0.686 (0.620-0.759) at 104 weeks

0.818 (0.745-0.898) at 130 weeks

0.249 (0.239-0.260) at 52 weeks

Age >70.

0.441 (0.332-0.586) at 156 weeks

0.441 (0.332-0.586) at 156 weeks

0.333 (0.146-0.761) at 52 weeks

0.133 (0.027-0.659) at 130 weeks

Age >75.

0.588 (0.374- 0.926) at 86 weeks

0.176 (0.052-0.597) at 130 weeks

Age >80.

0.294 (0.166-0.522) at 216 weeks

0.294 (0.166-0.522) at 156 weeks

Age 50-60.*

0.341 (0.215-0.542) at 86 weeks

0.366 (0.236-0.567) at 130 weeks

0.118 (0.041-0.339) at 156 weeks

Currently dialyzing through a catheter.

0.554 (0.446-0.688) at 104 weeks

0.246 (0.236-0.256) at 52 weeks

Diabetes Mellitus.

0.524 (0.422-0.651) at 44.5 weeks

0.598 (0.262-1.365) at 454 weeks

0.235 (0.198-0.278) at 52 weeks

Women.

0.062 (0.005-0.864) at 104 weeks

History of previous access failure.

0.578 (0.503-0.663) at 84.5 weeks

0.901 (0.850-0.956) at 104 weeks

Inflow artery minimum diameter 2-2.5 mm.

0.873 (0.810-0.940) at 26 weeks

0.958 (0.917-1.000) at 4 weeks

Men.

0 at 56 weeks

0 at 56 weeks

No Diabetes Mellitus.

0.366 (0.280-0.480) at 65 weeks

0.884 (0.804-0.972) at 936 weeks

0.207 (0.182-0.236) at 52 weeks

Non dominant side.

0.486 (0.324-0.729) at 26 weeks

0.367 (0.310-0.434) at 572 weeks

Pre-dialysis: anticipated start 1 year.

0.769 (0.696-0.850) at 104 weeks

Upper extremity minimum outflow vein diameter >3 mm.

0.900 (0.671-1.207) at 6 weeks

Upper extremity minimum outflow vein diameter 2.5-3 mm.

0.491 (0.426-0.565) at 104 weeks

Upper extremity minimum outflow vein diameter 2-2.5 mm.

0.873 (0.810-0.940) at 26 weeks

0.958 (0.917-1.000) at 4 weeks

* Results are mutually exclusive to this subgroup.

III.2: Upper arm AVF:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.535 (0.429-0.668) at 104 weeks

0.671 (0.545-0.826) at 104 weeks

0.698 (0.589-0.792) at 104 weeks

0.047 (0.001-1.646) at 104 weeks

0.972 (0.937-1.009) at 82 weeks

0 at 82 weeks

Age >70.

0.552 (0.384-0.792) at 104 weeks

III.3: Brachial- Basilic fistula:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.582 (0.511-0.664) at 104 weeks

0.722 (0.645-0.809) at 91 weeks

0.857 (0.736-0.998) at 65 weeks

0.104 (0.054-0.201) at 104 weeks

0.780 (0.685-0.888) at 34.15 weeks

0.019 (0.004-0.092) at 115 weeks

Age 65.

0.364 (0.144-0.915) at 52 weeks

Black.

0.600 (0.456-0.790) at 115 weeks

Diabetes Mellitus.

0.947 (0.862-1.041) at 52 weeks

0.84 (0.720-0.985) at 52 weeks

Women.

0.658 (0.422-1.025) at 109.5 weeks

Men.

0.933 (0.827-1.053) at 104 weeks

Non dominant side.

0.900 (0.671-1.207 ) at 43 weeks

0 at 43 weeks

0 at 43 weeks

Upper extremity minimum outflow vein diameter >3 mm.

0.900 (0.671-1.207) at 43 weeks

0 at 43 weeks

0 at 43 weeks

Upper extremity minimum outflow vein diameter 2.5-3 mm.

0.480(0.372-0.620) at 260 weeks

0.648 (0.574-0.732) at 260 weeks

0.042 (0.016-0.111) at 4 weeks

0.025 (0.007-0.093) at 121 weeks

III.4: Brachial-brachial fistula:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.586 (0.457- 0.751) at 92 weeks

0.455 (0.213-0.972) at 52 weeks

0.143 (0.03-0.363) at 125 weeks

0.213 (0.026-1.719) at 78 weeks

III.5: Brachial-Cephalic fistula:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.526 (0.458-0.604) at 130 weeks

0.573 (0.435-0.755) at 104.5 weeks

0.966 (0.950-0.983) at 260 weeks

0.325 (0.175-0.603) at 93.4 weeks

0.863 (0.588- 1.268) at 6 weeks

0.001 (0.000-0.685) at 130 weeks

Age 65.

0.452 (0.357-0.572) at 156 weeks

Age >80.

0.592 (0.329-1.065) at 156 weeks

0.429 (0.303-0.607) at 104 weeks

Age 60-70.

0.820 (0.753-0.894) at 208 weeks

Age 65-80.

0.543 (0.263-1.118) at 156 weeks

0.388 (0.307-0.491) at 105 weeks

BMI < 18.

0.686 (0.536-0.878) at 208 weeks

BMI > 25.

0.893 (0.845-0.943) at 208 weeks

BMI 18-25.

0.737 (0.682-0.796) at 208 weeks

Women.

0.772 (0.711-0.838) at 208 weeks

History of previous access failure.

0.802 (0.727-0.885) at 537 weeks

Men.

0.804 (0.756-0.854) at 208 weeks

Upper extremity minimum outflow vein diameter 2.5-3 mm.

0.394 (0.290-0.536) at 260 weeks

0.465 (0.357-0.606) at 260 weeks

0 at 4 weeks

0 at 121 weeks

III.6: Forearm AVF:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.460 (0.293-0.721) at 156 weeks

0.905 (0.869-0.941) at 260 weeks

0.431 (0.293-0.578) at 260 weeks

0 at 104 weeks

Diabetes Mellitus.

0.325 (0.249-0.423) at 208 weeks

0.823 (0.736-0.919) at 260 weeks

0.431 (0.293-0.578) at 260 weeks

No Diabetes Mellitus.

0.294 (0.121-0.714) at 260 weeks

0.922 (0.883-0.962) at 260 weeks

III.7: Radiocephalic fistula:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.554 (0.505-0.608) at 104 weeks

0.536 (0.423-0.679) at 104 weeks

0.858 (0.754-0.976) at 52 weeks

0.173 (0.114-0.263) at 104 weeks

0.781 (0.647-0.943)4 at 45.5 weeks

0.021 (0.007-0.064) at 156 weeks

Age 80.

0.383 (0.259-0.566) at 104 weeks

0.404 (0.278-0.588) at 104 weeks

Age 50-59.

0.364 (0.196-0.675) at 156 weeks

Age 60-69.

0.364 (0.222-0.596) at 156 weeks

Age 65-79.

0.359 (0.288-0.448) at 104 weeks

0.373 (0.301-0.462) at 104 weeks

Current Smoking

0.591 (0.400-0.873) at 78 weeks

Currently dialyzing through a catheter.

0.447 (0.374-0.535) at 260 weeks

Diabetes Mellitus.

0.373 (0.278-0.499) at 156 weeks

0.500 (0.337-0.741) at 104 weeks

Women.

0.200 (0.145-0.277) at 156 weeks

0.441 (0.292-0.667) at 104 weeks

0.857 (0.761-0.966) at 8 weeks

History of previous access failure.

0.680 (0.606-0.764) at 520 weeks

Inflow artery minimum diameter 2-2.5 mm.

0.745 (0.620-0.894) at 52 weeks

0.924 (0.854-1.000) at 8 weeks

Inflow artery minimum diameter >2.5 mm.

0.524 (0.383-0.716) at 52 weeks

Inflow artery minimum diameter 1.5-2 mm.

0.480 (0.352-0.655) at 52 weeks

0.857 (0.761-0.966) at 8 weeks

Left side.

0.474 (0.380-0.591) at 52 weeks

Men.

0.550 (0.437-0.693) at 156 weeks

0.730 (0.629-0.847) at 105 weeks

0.924 (0.854-1.000) at 8 weeks

Never Smoke.

0.825 (0.729-0.935) at 78 weeks

No Diabetes Mellitus.

0.533 (0.412-0.689) at 182 weeks

0.701 (0.600-0.819) at 104 weeks

Non dominant side.

0.452 (0.387-0.528) at 260 weeks

0.351 (0.290-0.425)

0.782 (0.681-0.897) at 42 weeks

Pre-dialysis: Anticipated start 6 months to 1 year.

0.532 (0.398-0.710) at 260 weeks

Pre-dialysis: Anticipated start in 1 year.

0.532 (0.398-0.710) at 260 weeks

Pre-dialysis: Anticipated start less than 6 months.

0.532 (0.398-0.710) at 260 weeks

Upper extremity minimum outflow vein diameter 67.

0.415 (0.410-0.420) at 52 weeks

Age >80.

0.600 (0.446-0.807) at 156 weeks

0.600 (0.446-0.807) at 156 weeks

Age 50-60.

0.429 (0.246-0.745) at 156 weeks

0.429 (0.246-0.745) at 156 weeks

History of previous access failure.

0.167 (0.083-0.285) at 29 weeks

III.16: Tunneled cuffed IJ/subclavian PermCath:

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.511 (0.411-0.637) at 82 weeks

0.763 (0.499-1.165) at 26 weeks

0.211 (0.130-0.343) at 116.5 weeks

0.163 (0.075-0.356) at 83.5 weeks

Age >70.

0.073 (0.038-0.140) at 78 weeks

0.102 (0.060-0.174) at 78 weeks

Age >75.

0.467(0.251-0.867) at 86 weeks

0.600 (0.373-0.966) at 130 weeks

III.17: Hybrid graft and catheter (HeRO):

Group

Primary Patency

Secondary Patency

Assisted Patency

Mortality

Maturation

Infection

Overall.

0.429 (0.361-0.510) at 104 weeks

0.704 (0.391-1.270) at 78 weeks

0.178 (0.128-0.248) at 122.8 weeks

0.038 (0.016-0.086) at 122.8 weeks

History of previous access failure.

0.091 (0.018-0.464) at 52 weeks

0.227 (0.094-0.547) at 52 weeks

HTN

0.091 (0.002-0.413) at 52 weeks

0.455 (0.167-0.766) at 52 weeks

Table IV: Average days to maturation:

Study ID

Sample size

Average number of days

Mean (95%CI)

Weighted SD

Cohort

Kybartiene, 2010Garcia Cortes, 2005

288

22.62 (21.26-23.99)

11.81

AVF, unspecified location. Overall.

Garcia Cortes, 2005

17

69.70 (51.64-87.76)

38.00

AVF, unspecified location. Age >75.

Rao, 2004Yilmaz, 2007Fitzgerald, 2004

119

92.55 (85.23- 99.88)

40.80

Brachial- basilic fistula.

Hruby, 2013Vahedian, 2012Alhassan, 2013

181

40.30 (38.72-41.88)

10.85

Radiocephalic fistula. Overall

Alhassan, 2013

97

30.80(28.57-33.03)

11.20

Radiocephalic fistula. Left hand.

Table V: Summary results of meta-analysis of included comparative studies per access types:5.1: AVF, unspecified location:

Study ID

Cohort 1

Cohort 2

Results

Persic, 2013

Age 65. DM

Age 65. No DM

Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.5 (0.26-0.96)

Secondary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.51 (0.21-1.22)

Segal, 2003

BMI 30

BMI Cohort 2. Not statistically significant, RR 1.09 (0.56-2.13)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.73 (0.34-1.54)

Ferring, 2010

No Cardiac disease

Cardiac disease

Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.033 (0.597-1.788)

Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.037 (0.555-1.936)

Ferring, 2010

non-Caucasian

Caucasian

Primary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.951 (0.579-1.564)

Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.364 (0.782-2.380)

Ferring, 2010

No DM

DM

Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.504 (0.965-2.344)

Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.657 (0.989-2.777)

Ferring, 2010. Segal, 2003

Women

Men

Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.607 (0.421-0.876)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.590 (0.254-1.369)

Segal, 2003

Coronary artery disease (CAD)

No CAD

Primary patency in Cohort 1 > Cohort 2. Statistically significant, RR 2.5 (1.08-5.56)

Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, RR 1.49 (0.58-3.85)

Segal, 2003

DM

No DM

Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.7 (0.37-1.33)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.93 (0.41-2.08)

Segal, 2003

Previous access

No Previous access

Primary patency in Cohort 1 < Cohort 2. Statistically significant, RR 0.49 (0.26-0.92)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.47 (0.22-1.02)

Segal, 2003

Smoking

No Smoking

Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.81 (0.38-1.67)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.53 (0.21-1.32)

Segal, 2003

Black

Non black

Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.56 (0.17-1.85)

Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.45 (0.12-1.75)

Ferring, 2010

Not yet on hemodialysis

On hemodialysis

Primary patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.196 (1.323-3.644)

Assisted patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.601 (1.473-4.594)

V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:

Study ID

Cohort 1

Cohort 2

Results

Ilhan, 2013. Lukowsky, 2012. Desilva, 2012

No subgroup reported.

No subgroup reported.

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.839 (0.421-1.675)

Desilva, 2012

African American

African American

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.63 (0.56-0.72)

Desilva, 2012

Age >90

Age >90

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.69 (0.52-0.91)

Desilva, 2012

Age 70 - 80

Age 70 - 80

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.56 (0.52-0.60)

Desilva, 2012

Age 81 - 90

Age 81 - 90

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.55 (0.51-0.59)

Desilva, 2012

Asian

Asian

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.50 (0.37-0.67)

Desilva, 2012

Comorbidity index 1 (0-8)

Comorbidity index 1 (0-8)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.52 (0.49-0.56)

Desilva, 2012

Comorbidity index 2 (=9)

Comorbidity index 2 (=9)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.61 (0.55-0.68)

Desilva, 2012

Comorbidity index 3 (>9)

Comorbidity index 3 (>9)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.57 (0.52-0.63)

Desilva, 2012

DM

DM

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.58 (0.54-0.62)

Desilva, 2012

Women

Women

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.59 (0.54-0.64)

Desilva, 2012

Men

Men

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.51-0.57)

Desilva, 2012

Native American

Native American

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.73 (0.40-1.32)

Desilva, 2012

No DM

No DM

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.53 (0.50-0.57)

Desilva, 2012

White

White

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.52-0.58)

V.3: Forearm AVF VS. Upper-arm AVF:

Study ID

Cohort 1

Cohort 2

Results

Ferring, 2010

Forearm AVF

Upper-arm AVF

Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.448 (0.277-0.724)

Assisted patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.491 (0.284-0.849)

V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:

Study ID

Cohort 1

Cohort 2

Results

Woo, 2012. Grubbs, 2013

Tunneled cuffed catheters, unspecified

Autogenous upper extremity AVF, unspecified

Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 3.148 (0.774-12.808)

Foley, 2009

African American

African American

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.19 (2.03-2.37)

Foley, 2009

Age >65

Age >65

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.14 (2.06-2.23)

Foley, 2009

Age 65

Age 65

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.31 (2.16-2.47)

Foley, 2009

Comorbid index 2

Comorbid index 2

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.03 (1.942.12)

Foley, 2009

Comorbid index 0 or 1

Comorbid index 0 or 1

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.37 (2.242.50)

Astor, 2005

Women

Women

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.96 (0.50 to 1.87)

Foley, 2009

Hispanic

Hispanic

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.23 (1.98-2.52)

Astor, 2005

Men

Men

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.98 (1.16 to 3.38)

Foley, 2009

White

White

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.18 (2.10-2.27)

V.5: AVG, unspecified location VS. AVF, unspecified location:

Study ID

Cohort 1

Cohort 2

Results

Woo, 2012. Grubbs, 2013. Pisoni, 2009

No subgroup reported.

No subgroup reported.

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.278 (1.139-1.435)

Foley, 2009

African American

African American

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.33 (1.20-1.49)

Foley, 2009

Age > 65

Age >65

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.36 (1.28-1.45)

Foley, 2009

Age 65

Age 65

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.47 (1.32-1.63)

Foley, 2009

Comorbid index 2

Comorbid index 2

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.32(1.231.42)

Foley, 2009

Comorbid index 0 or 1

Comorbid index 0 or 1

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38(1.261.51)

Astor, 2005

Women

Women

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.94 (0.51-1.72)

Foley, 2009

Hispanic

Hispanic

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38 (1.13-1.67)

Astor, 2005

Men

Men

Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 1.29 (0.75-2.22)

Foley, 2009

White

White

Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.44 (1.35-1.54)

V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:

Study ID

Cohort 1

Cohort 2

Results

Goldfarb-Rumyantze, 2013

Lukowsky, 2012

Desilva, 2012

No subgroup reported.

No subgroup reported.

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.922 (0.578-1.468)

Desilva, 2012

African American

African American

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.77 (0.67-0.89)

Desilva, 2012

Age >90

Age >90

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.83 (0.57-1.23)

Desilva, 2012

Age 70 - 80

Age 70 - 80

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.73 (0.66-0.80)

Desilva, 2012

Age 81 - 90

Age 81 - 90

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.74 (0.66-0.83)

Desilva, 2012

Asian

Asian

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.67 (0.47-0.95)

Desilva, 2012

Comorbidity index 1 (0-8)

Comorbidity index 1 (0-8)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.65 (0.58-0.73)

Desilva, 2012

Comorbidity index 2 (=9)

Comorbidity index 2 (=9)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.67-0.90)

Desilva, 2012

Comorbidity index 3 (>9)

Comorbidity index 3 (>9)

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.85 (0.74-0.96)

Desilva, 2012

DM

DM

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.71-0.86)

Desilva, 2012

Women

Women

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.68 (0.61-0.75)

Desilva, 2012

Men

Men

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.82 (0.74-0.91)

Desilva, 2012

Native American

Native American

Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.86 (0.27-2.73)

Desilva, 2012

No DM

No DM

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.70 (0.62-0.78)

Desilva, 2012

White

White

Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.73 (0.67-0.80)

References:

1.Cante P, Bottet P, Ryckelynck JP, Roch BL, Levaltier B, Lobbedez T, et al. [Distal vascular access for chronic hemodialysis in patients over 65 years of age. Surgical results]. Progres en Urologie. 1998;8(1):83-8.

2.Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001;60(4):1443-51.

3.Keuter XHA, Smet AAEAD, Kessels AGH, Sande FMvd, Welten RJTJ, Tordoir JHM. A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis. Journal of Vascular Surgery. 2008;47(2):395-401.

4.Ayala MD, Smith RM, Martone C, Briggs W, Deitch JS, Wise L. The effect of systemic anticoagulation in patients undergoing angioaccess surgery. Annals of Vascular Surgery. 2008;22(1):11-5.

5.Fassiadis N, Morsy M, Siva M, Marsh JE, Makanjuola AD, Chemla ES. Does the surgeon's experience impact on radiocephalic fistula patency rates? Seminars in Dialysis. 2007;20(5):455-7.

6.Elwakeel HA, Saad EM, Elkiran YM, Awad I. Unusual vascular access for hemodialysis: transposed venae comitante of the brachial artery. Annals of Vascular Surgery. 2007;21(5):560-3.

7.Keeling AN, Dwyer HO, Lyon S, Kelly PO, McGrath FP, Conlon PJ, et al. Do AshSplit haemodialysis catheters provide better flow rates in the long term? Renal Failure. 2007;29(6):721-9.

8.Nikeghbalian S, Bananzadeh A, Yarmohammadi H. Difficult vascular access in patients with end-stage renal failure. Transplantation Proceedings. 2006;38(5):1265-6.

9.Maya ID, Allon M. Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters. Kidney International. 2005;68(6):2886-9.

10.Rooijens PPGM, Burgmans JPJ, Yo TI, Hop WCJ, Smet AAEAd, Dorpel MAvd, et al. Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access. Journal of Vascular Surgery. 2005;42(3):481-6; discussions 7.

11.Madden RL, Lipkowitz GS, Browne BJ, Kurbanov A. A comparison of cryopreserved vein allografts and prosthetic grafts for hemodialysis access. Annals of Vascular Surgery. 2005;19(5):686-91.

12.Chen JC, Kamal DM, Jastrzebski J, Taylor DC. Venovenostomy for outflow venous obstruction in patients with upper extremity autogenous hemodialysis arteriovenous access. Annals of Vascular Surgery. 2005;19(5):629-35.

13.Akoh JA, Sinha S, Dutta S, Opaluwa AS, Lawson H, Shaw JF, et al. A 5-year audit of haemodialysis access. Int J Clin Pract. 2005;59(7):847-51.

14.Brueck M, Waeger S, Braig G, Kramer W. [Subcutaneously tunnelled cuffed venous hemodialysis catheters in chronic renal failure]. Deutsche Medizinische Wochenschrift. 2004;129(47):2529-34.

15.Iorio BRD, Bellizzi V, Cillo N, Cirillo M, Avella F, Andreucci VE, et al. Vascular access for hemodialysis: the impact on morbidity and mortality. Journal of Nephrology. 2004;17(1):19-25.

16.Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, et al. Basilic vein transposition fistula: a good option for maintaining hemodialysis access site options? Journal of Vascular Surgery. 2004;39(5):1043-7.

17.Kao CL, Chang JP. The reverse upper arm curved graft with ringed PTFE graft as an alternative vascular access procedure for hemodialysis. Journal of Cardiovascular Surgery. 2004;45(1):55-7.

18.Flarup S, Hadimeri H. Arteriovenous PTFE dialysis access in the lower extremity: a new approach. Annals of Vascular Surgery. 2003;17(5):581-4.

19.Segal JH, Kayler LK, Henke P, Merion RM, Leavey S, Campbell DA, et al. Vascular access outcomes using the transposed basilic vein arteriovenous fistula. American Journal of Kidney Diseases. 2003;42(1):151-7.

20.Gallieni M, Conz PA, Rizzioli E, Butti A, Brancaccio D. Placement, performance and complications of the Ash Split Cath hemodialysis catheter. International Journal of Artificial Organs. 2002;25(12):1137-43.

21.Hingorani A, Ascher E, Kallakuri S, Greenberg S, Khanimov Y. Impact of reintervention for failing upper-extremity arteriovenous autogenous access for hemodialysis. Journal of Vascular Surgery. 2001;34(6):1004-9.

22.Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance. Journal of Vascular Surgery. 2001;34(5):866-71.

23.Vogel KM, Martino MA, Brien SPO, Kerstein MD. Complications of lower extremity arteriovenous grafts in patients with end-stage renal disease. Southern Medical Journal. 2000;93(6):593-5.

24.Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney International. 1999;56(1):275-80.

25.Khadra MH, Dwyer AJ, Thompson JF. Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for hemodialysis access. American Journal of Surgery. 1997;173(4):280-3.

26.Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL. Vascular access for hemodialysis. Patency rates and results of revision. Annals of Surgery. 1985;202(2):235-9.

27.Rabbani A, Moini M, Shojaeefard A. Comparison between native arteriovenous fistula and graft in patients referred for hemodialysis access placement. Acta Medica Iranica. 2006;44 (6):395-9.

28.Senkaya I, Aytac IK, Percin B, Bicer M. Basilic vein transposition a good choice for vascular access for A-V fistulas. Chirurgia. 2006;19 (2):145-8.

29.Hood DB, Yellin AE, Richman MF, Weaver FA, Katz MD. Hemodialysis graft salvage with endoluminal stents. American Surgeon. 1994;60 (10):733-7.

30.Brunori G, Verzelletti F, Zubani R, Movilli E, Gaggiotti M, Cancarini G, et al. Which vascular access for chronic hemodialysis in uremic elderly patients? J Vasc Access. 2000;1(4):134-8.

31.Choi HM, Lal BK, Cerveira JJ, Padberg FT, Jr., Silva MB, Jr., Hobson RW, 2nd, et al. Durability and cumulative functional patency of transposed and nontransposed arteriovenous fistulas. J Vasc Surg. 2003;38(6):1206-12.

32.Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360(21):2191-201.

33.Matsuura JH, Rosenthal D, Clark M, Shuler FW, Kirby L, Shotwell M, et al. Transposed basilic vein versus polytetrafluorethylene for brachial-axillary arteriovenous fistulas. Am J Surg. 1998;176(2):219-21.

34.Silva MB, Jr., Hobson RW, 2nd, Pappas PJ, Jamil Z, Araki CT, Goldberg MC, et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg. 1998;27(2):302-7; discussion 7-8.

35.Staramos DN, Lazarides MK, Tzilalis VD, Ekonomou CS, Simopoulos CE, Dayantas JN. Patency of autologous and prosthetic arteriovenous fistulas in elderly patients. Eur J Surg. 2000;166(10):777-81.

36.Kokkosis AA, Abramowitz SD, Schwitzer J, Schanzer H, Teodorescu VJ. Experience of HeRO dialysis graft placement in a challenging population. Vascular & Endovascular Surgery. 2013;47(4):278-80.

37.Goldfarb-Rumyantzev AS, Yoon JH, Patibandla BK, Narra A, Sandhu GS, Desilva R. The role of initial hemodialysis vascular access in the outcome of subsequent kidney transplantation. Clinical Transplantation. 2013;27(2):210-6.

38.Al-Benna S, Deardon D, Hamilton D, El-Enin H. Long-term outcome of upper limb autogenous arteriovenous fistulas for hemodialysis access. Saudi Journal of Kidney Diseases & Transplantation. 2013;24(1):109-14.

39.Sahin L, Gul R, Mizrak A, Deniz H, Sahin M, Koruk S, et al. Ultrasound-guided infraclavicular brachial plexus block enhances postoperative blood flow in arteriovenous fistulas. Journal of Vascular Surgery. 2011;54(3):749-53.

40.Chiulli LC, Vasilas P, Dardik A. Superior patency of upper arm arteriovenous fistulae in high risk patients. Journal of Surgical Research. 2011;170(1):157-64.

41.Bonforte G, Rossi E, Auricchio S, Pogliani D, Mangano S, Mandolfo S, et al. The middle-arm fistula as a valuable surgical approach in patients with end-stage renal disease. Journal of Vascular Surgery. 2010;52(6):1551-6.

42.Ferring M, Claridge M, Smith SA, Wilmink T. Routine preoperative vascular ultrasound improves patency and use of arteriovenous fistulas for hemodialysis: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN. 2010;5(12):2236-44.

43.Kybartiene S, Skarupskiene I, Ziginskiene E, Kuzminskis V. Vascular access for hemodialysis: creation, functioning, and complications (data of the Hospital of Kaunas University of Medicine). Medicina (Kaunas, Lithuania). 2010;46(8):550-5.

44.Stuard S, Belcaro G, Dugall M, Cesarone MR, Hosoi M, Errichi BM, et al. Patency of arteriovenous fistula for dialysis improbe with topical spraygel heparin. Panminerva Medica. 2010;52(2 Suppl 1):33-6.

45.Garcia Cortes MJ, Viedma G, Sanchez Perales MC, Borrego FJ, Borrego J, Perez del Barrio P, et al. [Fistulae or catheter for elderly who start hemodialysis without permanent vascular access?]. Nefrologia. 2005;25(3):307-14.

46.Jimenez-Almonacid P, Rio JVD, Lasala M, Rueda JA, Vorwald P, Fernandez JM, et al. [First non-autologous vascular access for hemodialysis: PTFE fistula]. Nefrologia. 2004;24(6):559-63.

47.Hernandez-Jaras J, Garcia-Perez H, Torregrosa E, Pons R, Calvo C, Serra M, et al. [Outcome of tunneled hemodialysis catheters as permanent vascular access]. Nefrologia. 2004;24(5):446-52.

48.Rodriguez JA, Ferrer E, Olmos A, Codina S, Borrellas J, Piera L. [Analysis of the survival of permanent vascular access ports]. Nefrologia. 2001;21(3):260-73.

49.Branger B, Reboul P, Prelipcean C, Noguera ME, Cariou S, Granolleras C, et al. [Tunnelled internal jugular vein catheters with taurolidine lock: an acceptable challenge to arterio-venous fistula in 70 years old haemodialyzed patients: a prospective pilot study]. Nephrologie et Therapeutique. 2011;7(4):237-41.

50.Kennealey PT, Elias N, Hertl M, Ko DSC, Saidi RF, Markmann JF, et al. A prospective, randomized comparison of bovine carotid artery and expanded polytetrafluoroethylene for permanent hemodialysis vascular access. Journal of Vascular Surgery. 2011;53(6):1640-8.

51.Diehm N, Berg JCvd, Schnyder V, Buhler J, Willenberg T, Widmer M, et al. Determinants of haemodialysis access survival. Vasa. 2010;39(2):133-9.

52.Wasse H, Speckman RA, McClellan WM. Arteriovenous fistula use is associated with lower cardiovascular mortality compared with catheter use among ESRD patients. Seminars in Dialysis. 2008;21(5):483-9.

53.Ko PJ, Liu YH, Hung YN, Hsieh HC. Patency rates of cuffed and noncuffed extended polytetrafluoroethylene grafts in dialysis access: a prospective, randomized study. World Journal of Surgery. 2009;33(4):846-51.

54.Slayden GC, Spergel L, Jennings WC. Secondary arteriovenous fistulas: converting prosthetic AV grafts to autogenous dialysis access. Seminars in Dialysis. 2008;21(5):474-82.

55.Ekbal NJ, Swift PA, Chalisey A, Steele M, Makanjuola D, Chemla E. Hemodialysis access-related survival and morbidity in an elderly population in South West Thames, UK. Hemodialysis International. 2008;12 Suppl 2:S15-9.

56.Tsoulfas G, Hertl M, Ko DSC, Elias N, Delmonico FL, Romano L, et al. Long-term outcome of a cuffed expanded PTFE graft for hemodialysis vascular access. World Journal of Surgery. 2008;32(8):1827-31.

57.Long B, Bruyere F, Lermusiaux P, Culty T, Boutin JM, Artru B, et al. [Management of perianastomotic stenoses complicating vascular accesses for haemodialysis]. Progres en Urologie. 2008;18(7):462-9.

58.Qasaimeh GR, Qaderi SE, Omari GA, Badadweh MA. Vascular access infection among hemodialysis patients in Northern Jordan: incidence and risk factors. Southern Medical Journal. 2008;101(5):508-12.

59.Bronder CM, Cull DL, Kuper SG, Carsten CG, Kalbaugh CA, Cass A, et al. Fistula elevation procedure: experience with 295 consecutive cases during a 7-year period. Journal of the American College of Surgeons. 2008;206(5):1076-81; discussion 81-2.

60.Torina PJ, Westheimer EF, Schanzer HR. Brachial vein transposition arteriovenous fistula: is it an acceptable option for chronic dialysis vascular access? Journal of Vascular Access. 2008;9(1):39-44.

61.Shahnawaz, Ali S, Shahzad I, Baloch MU. Arterio venous fistula experience at a tertiary care hospital in Pakistan. Pakistan Journal of Medical Sciences. 2013;29 (1):161-5.

62.Morale W, Patane D, Incardona C, Seminara G, Messina M, Malfa P, et al. Venae comitantes as a potential vascular resource to create native arteriovenous fistulae. Journal of Vascular Access. 2011;12 (3):211-4.

63.Lee ES, Shen Q, Pitts RL, Guo M, Wu MH, Sun SC, et al. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation. Journal of Vascular Surgery. 2011;54 (2):454-60.

64.Moussavi SR, Tofigh AM. Comparing the saphenous vein with the Gore-tex bridge fistula in thigh for chronic hemodialysis. European Surgery - Acta Chirurgica Austriaca. 2007;39 (6):355-8.

65.Savader SJ, Haikal LC, Ehrman KO, Porter DJ, Oteham AC. Hemodialysis catheter-associated fibrin sheaths: Treatment with a low-dose rt-PA infusion. Journal of Vascular and Interventional Radiology. 2000;11 (9):1131-6.

66.Hurlbert SN, Mattos MA, Henretta JP, Ramsey DE, Barkmeier LD, Hodgson KJ, et al. Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: A prospective study that compares Impra versus Gore-tex grafts. Cardiovascular Surgery. 1998;6 (6):652-6.

67.McLaughlin K, Jones B, Mactier R, Porteus C. Long-term vascular access for hemodialysis using silicon dual-lumen catheters with guidewire replacement of catheters for technique salvage. American Journal of Kidney Diseases. 1997;29 (4):553-9.

68.Ozlem N, Karakayali S, Aydin R, Tibet HB. A new method of AV fistula construction in chronic hemodialysis patients: 'Distal snuffbox' AV fistulas. Dialysis and Transplantation. 1996;25 (2):82-6.

69.Tedoriya T, Urayama H, Katada S, Watanabe Y. A survey of vascular access for hemodialysis. Vascular Surgery. 1995;29 (2):123-7.

70.Beigi AA, Masoudpour H, Alavi M. The effect of ligation of the distal vein in snuff-box arteriovenous fistula. Saudi journal of kidney diseases and transplantation. 2009;20(6):1110-4.

71.Gormus N, Ozergin U, Durgut K, Yuksek T, Solak H. Comparison of autologous basilic vein transpositions between forearm and upper arm regions. Annals of Vascular Surgery. 2003;17(5):522-5.

72.Polo JR, Ligero JM, Diaz-Cartelle J, Garcia-Pajares R, Cervera T, Reparaz L. Randomized comparison of 6-mm straight grafts versus 6- to 8-mm tapered grafts for brachial-axillary dialysis access. Journal of Vascular Surgery. 2004;40(2):319-24.

73.Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y, Fodera M, et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg. 2000;31(1 Pt 1):84-92.

74.Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Journal of the American Society of Nephrology : JASN. 2005;16(5):1449-55.

75.Coburn MC, Carney WI, Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc Surg. 1994;20(6):896-902; discussion 3-4.

76.Haimov M, Burrows L, Schanzer H, Neff M, Baez A, Kwun K, et al. Experience with arterial substitutes in the construction of vascular access for hemodialysis. The Journal of cardiovascular surgery. 1980;21(2):149-54.

77.Hazinedaroglu SM, Tuzuner A, Ayli D, Demirer S, Duman N, Yerdel MA. Femoral vein transposition versus femoral loop grafts for hemodialysis: a prospective evaluation. Transplant Proc. 2004;36(1):65-7.

78.Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg. 1986;152(2):238-43.

79.Kim YS, Yang CW, Jin DC, Ahn SJ, Chang YS, Yoon YS, et al. Comparison of peritoneal catheter survival with fistula survival in hemodialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 1995;15(2):147-51.

80.Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ. Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int. 2001;60(4):1532-9.

81.Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM. Superiority of autogenous arteriovenous hemodialysis access: maintenance of function with fewer secondary interventions. Ann Vasc Surg. 2004;18(1):66-73.

82.Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. Journal of the American Society of Nephrology : JASN. 2004;15(2):477-86.

83.Ridao-Cano N, Polo JR, Polo J, Perez-Garcia R, Sanchez M, Gomez-Campdera FJ. Vascular access for dialysis in the elderly. Blood Purif. 2002;20(6):563-8.

84.Sparks SR, VanderLinden JL, Gnanadev DA, Smith JW, Bunt TJ. Superior patency of perforating antecubital vein arteriovenous fistulae for hemodialysis. Annals of Vascular Surgery. 1997;11 (2):165-7.

85.Tordoir JH, Kwan TS, Herman JM, Carol EJ, Jakimowicz JJ. Primary and secondary access surgery for haemodialysis with the Brescia-Cimino fistula and the polytetrafluoroethylene (PTFE) graft. Neth J Surg. 1983;35(1):8-12.

86.Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. Journal of Vascular Surgery. 1531;48(6):1524-31.

87.Flu H, Breslau PJ, Straaten JMK-v, Hamming JF, Lardenoye JWH. The effect of implementation of an optimized care protocol on the outcome of arteriovenous hemodialysis access surgery. Journal of Vascular Surgery. 2008;48(3):659-68.

88.Kakkos SK, Haddad GK, Haddad RK, Scully MM. Effectiveness of a new tunneled catheter in preventing catheter malfunction: a comparative study. Journal of Vascular & Interventional Radiology. 2008;19(7):1018-26.

89.Wu CC, Wen SC. Cutting balloon angioplasty for resistant venous stenoses of dialysis access: immediate and patency results. Catheterization & Cardiovascular Interventions. 2008;71(2):250-4.

90.Kakkos SK, Andrzejewski T, Haddad JA, Haddad GK, Reddy DJ, Nypaver TJ, et al. Equivalent secondary patency rates of upper extremity Vectra Vascular Access Grafts and transposed brachial-basilic fistulas with aggressive access surveillance and endovascular treatment. Journal of Vascular Surgery. 2008;47(2):407-14.

91.Jean-Baptiste E, Hassen-Khodja R, Haudebourg P, Declemy S, Batt M, Bouillanne PJ. Axillary loop grafts for hemodialysis access: midterm results from a single-center study. Journal of Vascular Surgery. 2008;47(1):138-43.

92.Schild AF, Perez EA, Gillaspie E, Patel AR, Noicely K, Baltodano N. Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease. Vascular & Endovascular Surgery. 2007;41(6):506-8.

93.Moossavi S, Regan JD, Pierson ED, Kasey JM, Tuttle AB, Vachharajani TJ, et al. Non-surgical salvage of thrombosed arterio-venous fistulae: a case series and review of the literature. Seminars in Dialysis. 2007;20(5):459-64.

94.Woo K, Farber A, Doros G, Killeen K, Kohanzadeh S. Evaluation of the efficacy of the transposed upper arm arteriovenous fistula: a single institutional review of 190 basilic and cephalic vein transposition procedures. Journal of Vascular Surgery. 2007;46(1):94-9; discussion 100.

95.Kayacioglu I, Baysal A, Ates M, Vural U, Balci AY, Saskin H, et al. The effect of the keyhole technique on diabetic patients undergoing autologous brachiobasilic transposition of an arteriovenous fistula. Heart Surgery Forum. 2007;10(2):E147-52.

96.Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J Am Soc Nephrol. 2007;18(6):1936-41.

97.Shemesh D, Goldin I, Berelowitz D, Zaghal I, Zigelman C, Olsha O. Blood flow volume changes in the maturing arteriovenous access for hemodialysis. Ultrasound in Medicine & Biology. 2007;33(5):727-33.

98.Basaran O, Atac FB, Karakayali F, Aliosmanoglu I, Yagmurdur MC, Ozdemir FN, et al. Endothelial nitric oxide synthase gene intron 4 (VNTR) polymorphism and vascular access graft thrombosis. Journal of Investigative Surgery. 2007;20(1):49-53.

99.Korten E, Toonder IM, Schrama YC, Hop WCJ, Ham ACvd, Wittens CHA. Dialysis fistulae patency and preoperative diameter ultrasound measurements. European Journal of Vascular & Endovascular Surgery. 2007;33(4):467-71.

100.Yilmaz M, Senkaya I, Saba D, Bicer M. Long-term outcomes of basilic vein transposition fistula for hemodialysis. Vasa. 2007;36(1):29-32.

101.Mitchell D, Krishnasami Z, Young CJ, Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrology Dialysis Transplantation. 2007;22(2):465-70.

102.Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, et al. Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clinical Journal of The American Society of Nephrology: CJASN. 2006;1(3):518-24.

103.Karakayali F, Basaran O, Ekici Y, Budakoglu I, Aytekin C, Boyvat F, et al. Effect of secondary interventions on patency of vascular access sites for hemodialysis. European Journal of Vascular & Endovascular Surgery. 2006;32(6):701-9.

104.Sayed HFE, Mendoza B, Meier GH, LeSar CJ, DeMasi RJ, Glickman MH, et al. Utility of basilic vein transposition for dialysis access. Vascular. 2005;13(5):268-74.

105.Fitzgerald JT, Schanzer A, McVicar JP, Chin AI, Perez RV, Troppmann C. Upper arm arteriovenous fistula versus forearm looped arteriovenous graft for hemodialysis access: a comparative analysis. Annals of Vascular Surgery. 2005;19(6):843-50.

106.Modarai B, Dasgupta P, Taylor J, Koffman G, Khan MS. Follow-up of polytetrafluoroethylene arteriovenous fistulae for haemodialysis. International Journal of Clinical Practice. 2005;59(9):1005-7.

107.Kizilisik AT, Kim SB, Nylander WA, Shaffer D. Improvements in dialysis access survival with increasing use of arteriovenous fistulas in a Veterans Administration medical center. American Journal of Surgery. 2004;188(5):614-6.

108.Ko PJ, Hsieh HC, Chu JJ, Lin PJ, Liu YH. Patency rates and complications of Exxcel yarn-wrapped polytetrafluoroethylene grafts versus Gore-tex stretch polytetrafluoroethylene grafts: a prospective study. Surgery Today. 2004;34(5):409-12.

109.Fitzgerald JT, Schanzer A, Chin AI, McVicar JP, Perez RV, Troppmann C. Outcomes of upper arm arteriovenous fistulas for maintenance hemodialysis access. Archives of Surgery. 2004;139(2):201-8.

110.Mazzoni G, Frattarelli D, Iafrancesco D, Vagni V, Morosetti M, Farao RM. [Arteriovenous brachio-basilic fistula as hemodialysis port. Original technique and long term results]. Giornale di Chirurgia. 2003;24(10):371-6.

111.Senkaya I, Aytac II, Eercan AK, Aliosman A, Percin B. The graft selection for haemodialysis. Vasa. 2003;32(4):209-13.

112.Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. American Journal of Kidney Diseases. 2003;42(5):1013-9.

113.Shenoy S, Miller A, Petersen F, Kirsch WM, Konkin T, Kim P, et al. A multicenter study of permanent hemodialysis access patency: beneficial effect of clipped vascular anastomotic technique. Journal of Vascular Surgery. 2003;38(2):229-35.

114.Bruns SD, Jennings WC. Proximal radial artery as inflow site for native arteriovenous fistula. Journal of the American College of Surgeons. 2003;197(1):58-63.

115.Wiese P, Blume J, Mueller HJ, Renner H, Nonnast D, Barbara. Clinical and Doppler ultrasonography data of a polyurethane vascular access graft for haemodialysis: a prospective study. Nephrology Dialysis Transplantation. 2003;18(7):1397-400.

116.Baldrati L, Pascalis AD, Giudicissi A, Docci D, Neri L, Feletti C. [Pre-dialysis arteriovenous fistula results in better patency rate]. Giornale Italiano di Nefrologia. 2003;20(2):166-9.

117.Hossny A. Brachiobasilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-related complications. Journal of Vascular Surgery. 2003;37(4):821-6.

118.Dalman RL, Harris EJ, Jr, Victor BJ, Coogan SM. Transition to all-autogenous hemodialysis access: the role of preoperative vein mapping. Annals of Vascular Surgery. 2002;16(5):624-30.

119.Sorom AJ, Hughes CB, McCarthy JT, Jenson BM, Prieto M, Panneton JM, et al. Prospective, randomized evaluation of a cuffed expanded polytetrafluoroethylene graft for hemodialysis vascular access. Surgery. 2002;132(2):135-40.

120.Ascher E, Hingoran A, Gunduz Y, Yorkovich Y, Ward M, Miranda J, et al. The value and limitations of the arm cephalic and basilic vein for arteriovenous access. Ann Vasc Surg. 2001;15(1):89-97.

121.Wolowczyk L, Williams AJ, Donovan KL, Gibbons CP. The snuffbox arteriovenous fistula for vascular access. European Journal of Vascular & Endovascular Surgery. 2000;19(1):70-6.

122.Taylor SM, Eaves GL, Weatherford DA, McAlhany JC, Jr, Russell HE, et al. Results and complications of arteriovenous access dialysis grafts in the lower extremity: a five year review. American Surgeon. 1996;62(3):188-91.

123.Helling TS, Nelson PW, Shelton L. A prospective evaluation of plasma-TFE and expanded PTFE grafts for routine and early use as vascular access during hemodialysis. Annals of Surgery. 1992;216(5):596-9.

124.Nannery WM, Stoldt HS, Fares LG, nd. Hemodialysis access operations performed upon patients with human immunodeficiency virus. Surgery, Gynecology & Obstetrics. 1991;173(5):387-90.

125.Donnelly PK, Hoenich NA, Lennard TW, Proud G, Taylor RM. Surgical management of long-term central venous access in uraemic patients. Nephrology Dialysis Transplantation. 1988;3(1):57-65.

126.Rizzuti RP, Hale JC, Burkart TE. Extended patency of expanded polytetrafluoroethylene grafts for vascular access using optimal configuration and revisions. Surgery, Gynecology & Obstetrics. 1988;166(1):23-7.

127.Elwakeel H, Khafagy T, Regal S, Saad E. Prosthetic axillary-axillary arm loop arteriovenous graft for hemodialysis. International Angiology. 2013;32(6):589-92.

128.Nadeau-Fredette AC, Goupil R, Montreuil B, Carignan A, Leblanc M. Arteriovenous fistula for the 80 years and older patients on hemodialysis: is it worth it? Hemodialysis International. 2013;17(4):594-601.

129.Scarritt T, Paragone CM, Gorman RBO, Kyriazis DK, Maltese C, Rostas JW, et al. Traditional versus early-access grafts for hemodialysis access: a single-institution comparative study. American Surgeon. 2014;80(2):155-8.

130.Hruby Z, Stanek-Piotrowska M, Turek J, Witkiewicz W, Jonkisz A, Konieczny A, et al. The clinicopathological determinants of native arteriovenous fistula failure in patients on maintenance hemodialysis. Advances in Clinical & Experimental Medicine. 2013;22(4):495-500.

131.Kanko M, Sen C, Yavuz S, Unal C, Aksoy A, Berki T. Evaluation of arteriovenous fistulas made with the diamond-shaped anastomosis technique. Medical Science Monitor. 2012;18(9):MT67-70.

132.Gage SM, Katzman HE, Ross JR, Hohmann SE, Sharpe CA, Butterly DW, et al. Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment. European Journal of Vascular & Endovascular Surgery. 2012;44(1):93-9.

133.Basel H, Ekim H, Odabasi D, Kiymaz A, Aydin C, Dostbil A. Basilic vein transposition fistulas versus prosthetic bridge grafts in patients with end-stage renal failure. Annals of Vascular Surgery. 2011;25(5):634-9.

134.Walker SR. U Clips for arteriovenous anastomosis: a pilot, randomized study. ANZ Journal of Surgery. 2012;82(9):630-2.

135.Huddam B, Azak A, Kocak G, Ortabozkoyun L, Duranay M. The efficacy of prophylactic antibiotics administration prior to insertion of tunneled catheter in hemodialysis patients. Renal Failure. 2012;34(8):998-1001.

136.Woo K, Yao J, Selevan D, Hye RJ. Influence of vascular access type on sex and ethnicity-related mortality in hemodialysis-dependent patients. Perm J. 2012;16(2):4-9.

137.Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Patterns and predictors of early mortality in incident hemodialysis patients: new insights. American Journal of Nephrology. 2012;35(6):548-58.

138.Solid CA, Carlin C. Timing of arteriovenous fistula placement and Medicare costs during dialysis initiation. American Journal of Nephrology. 2012;35(6):498-508.

139.Matsumoto H, Yamamoto E, Kamiya C, Miura E, Kitaoka T, Suzuki J, et al. Early use of brachial-basilic arteriovenous fistula. Journal of Vascular Access. 2012;13(2):251-5.

140.DeSilva RN, Sandhu GS, Garg J, Goldfarb-Rumyantzev AS. Association between initial type of hemodialysis access used in the elderly and mortality. Hemodialysis International. 2012;16(2):233-41.

141.Vahedian J, Jalayifar AM, Keramati MR, Nabavizadeh F, Vahedian M. Primary success of bifurcated vein patch arteriovenous fistula and Brescia-Cimino methods. Iranian journal of Kidney Diseases. 2012;6(2):124-8.

142.Jackson RS, Sidawy AN, Amdur RL, Khetarpal A, Macsata RA. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement. Journal of Vascular Surgery. 2011;54(6):1706-12.

143.Chan KE, Pflederer TA, Steele DJR, Lilly MP, Ikizler TA, Maddux FW, et al. Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty. Clinical Journal of The American Society of Nephrology: CJASN. 2011;6(11):2669-80.

144.Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH. Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. Journal of Vascular Surgery. 2011;54(5):1383-9.

145.Powell S, Chan TY, Bhat R, Lam K, Narlawar RS, Cullen N, et al. A retrospective comparative study of tunneled haemodialysis catheters inserted through occluded or collateral veins versus conventional methods. Cardiovascular & Interventional Radiology. 2010;33(4):744-50.

146.Karakayali F, Ekici Y, Gorur SK, Arat Z, Boyvat F, Karakayali H, et al. The value of preoperative vascular imaging in the selection and success of hemodialysis access. Annals of Vascular Surgery. 2007;21(4):481-9.

147.Hamida FB, Hibik SM, Karoui C, Abderrahim E, Kaaroud H, Beji S, et al. [Indications, complications and cost of internal jugular catheters in hemodialysed patients: study of 533 cases]. Tunisie Medicale. 2005;83(9):519-23.

148.Cetinkaya R, Odabas AR, Unlu Y, Selcuk Y, Ates A, Ceviz M. Using cuffed and tunnelled central venous catheters as permanent vascular access for hemodialysis: a prospective study. Renal Failure. 2003;25(3):431-8.

149.Gorski TF, Gorski YC, Muney J. Complications of hemodialysis access in HIV-positive patients. American Surgeon. 2002;68(12):1104-6.

150.Ravani P, Marcelli D, Malberti F. Vascular access surgery managed by renal physicians: the choice of native arteriovenous fistulas for hemodialysis. American Journal of Kidney Diseases. 2002;40(6):1264-76.

151.Bacchini G, Vecchio LD, Andrulli S, Pontoriero G, Locatelli F. Survival of prosthetic grafts of different materials after impairment of a native arteriovenous fistula in hemodialysis patients. ASAIO Journal. 2001;47(1):30-3.

152.Friedm